November 29, 2018 07:43 AM EST

After getting beat up on its depression drug pitch, a battered Alkermes pivots to schizophrenia with a positive PhIII readout — but skeptics are ready to pounce

John Carroll

Editor & Founder

Badly needing a new focus after regulators and experts slapped around their pitch for the depression drug ALKS-5461, Alkermes $ALKS is changing the topic today …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After getting beat up on its depression drug pitch, a battered Alkermes pivots to schizophrenia with a positive PhIII readout — but skeptics are ready to pounce

John Carroll

Editor & Founder

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

FDA inspectors discover trucks carrying torn-up records leaving Indian generics factory

Aligos’ trial for oral MASH treatment succeeds, but placebo group shows odd trend

Lasker Award goes to three scientists who pioneered research behind GLP-1 drugs

Roche outlines commercial manufacturing strategy for GLP-1/GIP assets

Exclusive: Flagship-backed Valo Health loses interim CEO ahead of key Phase 2 readout

Breaking down silos with a new quantitative approach to drug development

Af­ter get­ting beat up on its de­pres­sion drug pitch, a bat­tered Alk­er­mes piv­ots to schiz­o­phre­nia with a pos­i­tive PhI­II read­out — but skep­tics are ready to pounce

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

After getting beat up on its depression drug pitch, a battered Alkermes pivots to schizophrenia with a positive PhIII readout — but skeptics are ready to pounce